Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 554 | -54,836 | -62,255 | -94,660 | -122,725 |
| Depreciation Amortization | 16,066 | 15,632 | 15,365 | 14,227 | 2,840 |
| Income taxes - deferred | N/A | -2,268 | -1,249 | -1,424 | 0 |
| Accounts receivable | -10,635 | -1,218 | -8,367 | -13,374 | -6,237 |
| Accounts payable and accrued liabilities | -69 | -9,613 | 6,959 | -4,318 | 5,527 |
| Other Working Capital | -10,360 | -8,820 | -6,294 | -35,150 | 11,854 |
| Other Operating Activity | 33,070 | 24,142 | 8,818 | 31,808 | 13,206 |
| Operating Cash Flow | $28,626 | $-36,981 | $-47,023 | $-102,891 | $-95,535 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | 5,751 | -3,741 | 34,985 | 60,580 |
| PPE Investments | -696 | -868 | -2,263 | -524 | -1,085 |
| Net Acquisitions | N/A | N/A | N/A | N/A | 38,469 |
| Investing Cash Flow | $-696 | $4,883 | $-6,004 | $34,461 | $97,964 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 50,000 | N/A | 146,214 | N/A |
| Debt Repayment | N/A | N/A | N/A | -43,496 | 0 |
| Common Stock Issued | 22,265 | 1,733 | 581 | 836 | 835 |
| Common Stock Repurchased | -10,876 | -3,734 | -1,009 | -468 | -534 |
| Other Financing Activity | 0 | -11,831 | -1,185 | 24,387 | 26,946 |
| Financing Cash Flow | $11,389 | $36,168 | $-1,613 | $127,473 | $27,247 |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | -3 |
| Beginning Cash Position | 75,744 | 71,674 | 126,314 | 67,271 | 37,598 |
| End Cash Position | 115,063 | 75,744 | 71,674 | 126,314 | 67,271 |
| Net Cash Flow | $39,319 | $4,070 | $-54,640 | $59,043 | $29,673 |
| Free Cash Flow | |||||
| Operating Cash Flow | 28,626 | -36,981 | -47,023 | -102,891 | -95,535 |
| Capital Expenditure | -696 | -868 | -2,263 | -524 | -1,085 |
| Free Cash Flow | 27,930 | -37,849 | -49,286 | -103,415 | -96,620 |